S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NYSE:ALC

Alcon (ALC) Stock Price, News & Analysis

$79.00
-0.61 (-0.77%)
(As of 04/17/2024 ET)
Today's Range
$78.82
$79.95
50-Day Range
$74.84
$88.15
52-Week Range
$69.44
$88.23
Volume
1.16 million shs
Average Volume
913,303 shs
Market Capitalization
$38.95 billion
P/E Ratio
40.31
Dividend Yield
N/A
Price Target
$91.22

Alcon MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
15.5% Upside
$91.22 Price Target
Short Interest
Bearish
0.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Alcon in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.77%
From $3.05 to $3.47 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

492nd out of 914 stocks

Ophthalmic Goods Industry

5th out of 7 stocks

ALC stock logo

About Alcon Stock (NYSE:ALC)

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

ALC Stock Price History

ALC Stock News Headlines

Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
Star Surgical Shines as U.S. Outlook Improves for 2024 (ALC)
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Hawaii-based clothing brand opens fifth location
Swiss Market Ends On Firm Note After Soft Inflation Data
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
MLK Middle School holds 'Diamond' pageant
Swiss Market Ends On Weak Note
Swiss Market Ends On Weak Note; Swisscom Rallies Sharply
See More Headlines
Receive ALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alcon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Facilities
CUSIP
04544X30
Employees
25,000
Year Founded
1945

Price Target and Rating

Average Stock Price Target
$91.22
High Stock Price Target
$100.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+14.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
14 Analysts

Profitability

Net Income
$974 million
Pretax Margin
8.80%

Debt

Sales & Book Value

Annual Sales
$9.46 billion
Cash Flow
$5.15 per share
Book Value
$41.83 per share

Miscellaneous

Free Float
N/A
Market Cap
$39.26 billion
Optionable
Optionable
Beta
0.91

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. F. Michael Ball (Age 69)
    Executive Chairman
    Comp: $1.17M
  • Mr. Arthur B. Cummings M.D. (Age 62)
    Executive Director
    Comp: $284.68k
  • Mr. David J. Endicott (Age 59)
    CEO & Director
    Comp: $4.82M
  • Mr. Timothy C. Stonesifer (Age 57)
    Chief Financial Officer
  • Margaret Buckley
    Chief Accounting Officer
  • Dr. Franck Leveiller
    Senior VP, Head of Global R&D and Chief Scientific Officer
  • Ms. Sue-Jean Lin (Age 65)
    Senior VP and Chief Information & Transformation Officer
  • Mr. Royce R. Bedward (Age 58)
    Senior VP, General Counsel & Corporate Secretary
  • Ms. Kimberly Martin (Age 49)
    Senior VP, Chief HR Officer & Corporate Communications
  • Mr. Laurent Attias (Age 56)
    Head of Corporate Development, Strategy, BD&L and M&A

Should I Buy Alcon Stock? ALC Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alcon Inc.:

  • Alcon's recent launch of the Clareon Presbyopia Correcting IOLs in India showcases the company's commitment to innovation in the intraocular lens technology market.
  • The company's diverse product portfolio, including cataract products like the Centurion vision system and refractive surgery products like WaveLight lasers, positions it well in the ophthalmic goods industry.
  • Alcon's strong presence in the global eye care market, with a focus on providing solutions for eye care professionals and patients worldwide, offers stability and growth potential.
  • Investors may find Alcon's focus on developing advanced technology IOLs for the correction of presbyopia and astigmatism during cataract surgery appealing, considering the increasing demand for such products.
  • Considering the current stock price and the company's continuous efforts in research, development, and expansion, Alcon Inc. presents an opportunity for potential growth in the health care facilities subindustry.

Cons

Investors should be bearish about investing in Alcon Inc. for these reasons:

  • Market competition in the ophthalmic goods industry is intense, which could potentially impact Alcon's market share and profitability.
  • Regulatory challenges and changes in health care policies globally may pose risks to Alcon's operations and product approvals, affecting its financial performance.
  • Fluctuations in foreign exchange rates could impact the company's revenue and profitability, especially considering its global presence and sales in various countries.
  • Investing in medical device companies like Alcon carries inherent risks related to product recalls, lawsuits, and regulatory compliance, which could affect investor confidence and financial stability.
  • While Alcon's focus on innovation is a strength, it also requires continuous investment in research and development, which could impact short-term profitability and cash flow.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Alcon pros and cons to contact@marketbeat.com.

ALC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alcon stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALC shares.
View ALC analyst ratings
or view top-rated stocks.

What is Alcon's stock price target for 2024?

14 brokers have issued twelve-month price targets for Alcon's shares. Their ALC share price targets range from $65.00 to $100.00. On average, they anticipate the company's share price to reach $91.22 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for ALC
or view top-rated stocks among Wall Street analysts.

How have ALC shares performed in 2024?

Alcon's stock was trading at $78.12 at the beginning of 2024. Since then, ALC stock has increased by 1.1% and is now trading at $79.00.
View the best growth stocks for 2024 here
.

Are investors shorting Alcon?

Alcon saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,320,000 shares, an increase of 9.1% from the March 15th total of 3,960,000 shares. Based on an average daily trading volume, of 929,300 shares, the short-interest ratio is presently 4.6 days. Approximately 0.9% of the company's shares are short sold.
View Alcon's Short Interest
.

When is Alcon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ALC earnings forecast
.

How were Alcon's earnings last quarter?

Alcon Inc. (NYSE:ALC) issued its earnings results on Tuesday, February, 27th. The healthcare company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.02. The healthcare company had revenue of $2.33 billion for the quarter, compared to analyst estimates of $2.34 billion. Alcon had a net margin of 10.30% and a trailing twelve-month return on equity of 6.75%. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.42 EPS.

How often does Alcon pay dividends? What is the dividend yield for Alcon?

Alcon declared an annual dividend on Friday, May 5th. Stockholders of record on Thursday, May 11th will be paid a dividend of $0.1365 per share on Friday, May 12th. This represents a yield of 0.21%. The ex-dividend date of this dividend is Wednesday, May 10th. This is an increase from the stock's previous annual dividend of $0.13.
Read our dividend analysis for ALC
.

What ETF holds Alcon's stock?

BlackRock Future Health ETF holds 2,110 shares of ALC stock, representing 2.99% of its portfolio.

What guidance has Alcon issued on next quarter's earnings?

Alcon issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 3.000-3.100 for the period, compared to the consensus earnings per share estimate of 3.040. The company issued revenue guidance of $9.9 billion-$10.1 billion, compared to the consensus revenue estimate of $10.0 billion.

What is Greg D. Wight's approval rating as Alcon's CEO?

6 employees have rated Alcon Chief Executive Officer Greg D. Wight on Glassdoor.com. Greg D. Wight has an approval rating of 100% among the company's employees. This puts Greg D. Wight in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and AbbVie (ABBV).

Who are Alcon's major shareholders?

Alcon's stock is owned by a number of retail and institutional investors. Top institutional investors include AMF Tjanstepension AB (0.70%), Banque Cantonale Vaudoise (0.23%), Douglas Lane & Associates LLC (0.02%), Shorepath Capital Management LLC (0.01%), Chesley Taft & Associates LLC (0.01%) and Gateway Investment Advisers LLC (0.01%).

How do I buy shares of Alcon?

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alcon have any subsidiaries?
The following companies are subsidiares of Alcon: Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.
Read More
This page (NYSE:ALC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners